LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

GE HealthCare Unveils Sonic DL for 3D, Expanding Deep Learning Innovations in MRI

December 01, 2024 | Last Trade: US$77.09 2.16 -2.73
  • New 3D imaging capabilities of Sonic DL are designed to enable up to 86%i faster scans and enhanced resolution for brain, spine, orthopedic and body imaging.
  • Combination of Sonic DL and AIR Recon DL accelerates workflow while improving diagnostic confidence and patient comfort.

CHICAGO / Dec 01, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) today unveiled Sonic DL for 3Dii, the newest addition to its effortless imaging portfolio, designed to accelerate MRI scans across a wide range of clinical applications. Sonic DL for 3D builds on GE HealthCare’s deep learning innovation legacy and the success of AIR Recon DL, which has helped over 34 million patients to date. Initially launched in 2023 for Cardiac MRI, Sonic DL provides up to 12 times scan acceleration while maintaining diagnostic qualityiii. Now, GE HealthCare is extending Sonic DL to 3D volumetric imaging, designing it to broaden its applicability to brain, spine, orthopedic and body exams, in addition to cardiac. This expansion is intended to retain the same impressive 12x acceleration and reduce scan times by up to 86%.

Healthcare burnout has reached critical levels, with 63% of physicians and 49% of nurses reporting symptoms of burnout, according to a 2023 American Medical Association (AMA) surveyiv. Rising workloads, time constraints, and staffing shortages contribute to high stress and fatigue among healthcare professionals, directly impacting patient care. Addressing these challenges, Sonic DL for 3D is designed to help enable faster, high-quality imaging for a majorityv of MR exams. By combining Sonic DL’s speed with AIR Recon DL’svi noise reduction technology, this deep learning integration is intended to empower clinicians to significantly cut scan times, enhance image resolution by up to 55%, and enable faster, accurate diagnoses with greater ease.

In neurology, Sonic DL 3D is designed to enable high-resolution imaging of complex brain structures, allowing for quicker, clearer insights into neurological conditions. In orthopedics, it will help to speed up the imaging of joints, ligaments, and bones, reducing scan times to minimize patient discomfort, especially for those with mobility challenges. By advancing speed and clarity in these critical areas, Sonic DL 3D helps to enhance clinical workflows, improve patient comfort, and support timely diagnoses.

“Today’s unveiling of Sonic DL for 3D reinforces our commitment to advancing medical imaging,” said Kelly Londy, President & CEO, Global MR, GE HealthCare. “Our deep learning, effortless imaging portfolio has already seen great success with AIR Recon DL and Sonic DL for cardiac. Now, with Sonic DL’s expansion to 3D and its ability to combine with AIR Recon DL, we’re offering a combination of speed, accuracy, and clarity. We believe Sonic DL will be a game-changer in key clinical areas, substantially impacting our customers' ability to deliver high-quality care while enhancing the capabilities of their existing systems through seamless upgrades.”

GE HealthCare’s ongoing investment in deep learning technologies, available for both in-field MR upgrades and new installations, supports its vision of sustainable and equitable MR access. By equipping facilities with faster, high-quality imaging solutions, GE HealthCare aims to help healthcare providers reduce patient backlogs, increase exam capacity, and deliver more cost-effective care.

With Sonic DL’s extended capabilities in 3D imaging, GE HealthCare continues to lead as a top provider of AI-integrated MR technology, supporting clinicians in delivering precise, timely diagnostics while enhancing the patient experiencevii.

Learn more about Sonic DL 3D at the Radiological Society of North America (RSNA) Annual Meeting, December 1–4, 2024, in Chicago, or online at gehealthcare.com.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

i

 

Internal Data on file; Product Data Sheet Reference DOC3050862

ii

 

Sonic DL for 3D is 510(k) pending at the US FDA. Not yet CE Marked. Not available for sale in all regions.

iii

 

GE HealthCare data on file

iv

 

http://www.ama-assn.org/practice-management/physician-health/5-things-health-care-organizations-learned-about-burnout-year

v

 

Data on File, REF-06122

vi

 

https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcares-air-recon-dl-receives-fda-clearance-of-3d-and-motion-insensitive?npclid=botnpclid&srsltid=AfmBOoofhQrkegrnQapO24VI5GFj9NGha52mArf78AKq6kw5w_vG22fR

vii

 

https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcare-tops-list-for-third-year-in-a-row-with-highest-number-of-ai-enabled-medical-device-authorizations

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB